Alemtuzumab for treating relapsing‑remitting multiple sclerosis

NICE technology appraisal guidance [TA312] Published date:

Alemtuzumab is recommended as a possible treatment for people with active relapsing–remitting multiple sclerosis.

What does this mean for me?

If you have active relapsing–remitting multiple sclerosis, and your doctor thinks that alemtuzumab is the right treatment, you should be able to have the treatment on the NHS.

Alemtuzumab should be available on the NHS within 3 months of the guidance being issued.

Get involved